Is Align Technology (ALGN) Fully Priced As EU Antitrust Scrutiny Clouds Its Valuation?
Align Technology (ALGN) is under increased scrutiny due to an EU antitrust investigation into its iTero scanners and Invisalign ecosystem. While the stock has seen short-term price increases, longer-term returns are negative. Valuation models show conflicting results, with one narrative suggesting it's 19.3% overvalued at $154.62, while a discounted cash flow model suggests it's 37.1% undervalued at $293.18.
Is Align Technology (ALGN) Fully Priced As EU Antitrust Scrutiny Clouds Its Valuation?
Align Technology (ALGN) is facing new antitrust scrutiny from the European Commission, which could impact its valuation. While the company has shown short-term share price momentum, its long-term returns are down. Different valuation narratives exist, with one suggesting ALGN is overvalued at $154.62, factoring in inflation and competition, and another DCF model suggesting it is undervalued at $293.18, trading at a 37.1% discount.
LSV CONSERVATIVE VALUE EQUITY FUND's Align Technology Inc(ALGN) Holding History
LSV CONSERVATIVE VALUE EQUITY FUND holds 3,000 shares of Align Technology Inc (ALGN), valued at $528,030 as of April 30, 2026, representing 0.34% of its portfolio. The fund acquired these shares through one purchase in Q2 2026 at an average price of $179.84. Based on the current ALGN price of $184.52, the estimated gain on this holding is $14,040, or 2.60%.
If You Invested $1,000 in Repligen (RGEN)
This article analyzes the historical performance of investing $1,000 in Repligen (RGEN) over 1, 5, and 10 years, detailing the total return and Compound Annual Growth Rate (CAGR). It also provides an annual performance comparison of RGEN against the S&P 500 and offers a company overview, including its business focus, products, global operations, and financial reporting. The article concludes by highlighting key themes in Repligen's public communications and its industry classification within the life sciences sector.
ALGN - Align Technology Inc Volatility & Greeks
This article provides a detailed financial overview of Align Technology Inc (ALGN), including its stock performance, key financial metrics, valuation ratios, and insider/institutional ownership data. It highlights the company's recent closing price, percentage change, and various profitability and efficiency ratios.
Should You Continue to Hold ILMN Stock in Your Portfolio?
Illumina Inc. (ILMN) is poised for growth due to its focus on core sequencing, multiomics expansion, and strong NovaSeq X placements, despite challenges in the China market and macroeconomic pressures. The company surpassed Q1 2026 estimates, raised full-year guidance, and sees clinical end markets as a key driver for demand. Analysts forecast continued revenue and EPS growth, making ILMN a Zacks Rank #3 (Hold) stock.
The Vivera Retainers from Align Technology - quiet revenue driver in long-term smile care
Align Technology's Vivera Retainers are a significant, albeit quiet, revenue driver for the company. These custom clear trays prevent teeth from drifting after Invisalign treatment, generating recurring sales through reorders based on stored digital data. While patients pay an out-of-pocket premium, the convenience and discreet nature of Vivera retainers make them a popular choice, contributing to Align Technology's steady long-term revenue.
COO - Cooper Companies Inc Options
This article provides a detailed financial overview of Cooper Companies Inc (COO), including its last close price, various financial ratios, performance metrics, and insider/institutional ownership data. It lists key financial figures such as market cap, income, sales, P/E ratio, and EPS, alongside stock performance over different periods and analyst recommendations.
Align Tech defends practices, pledges cooperation with EU probe
Align Technology announced it is cooperating with the European Commission's antitrust investigation into its business practices. The company stated it believes its operations comply with all applicable laws and regulations, and is committed to demonstrating this to the Commission. The probe is examining whether Align has hindered competition in the clear aligner and imaging services markets.
Align Technology Inc (ALGN) Stock Up 7.6% and Still Undervalued -- GF Score: 89/100
Align Technology Inc (ALGN) saw its stock rise 7.6% on July 1, 2026, reaching $181.49. Despite the gain, the stock is considered "Modestly Undervalued" with a GF Value™ estimate of $239.72, suggesting a 24.3% margin of safety. The company boasts a strong GF Score™ of 89/100, driven by excellent profitability, and has not seen any insider transactions in the last three months, indicating stability.
Align Technology Inc. stock outperforms competitors on strong trading day
Shares of Align Technology Inc. (ALGN) rose 7.61% to $181.49 on Wednesday, outperforming the broader market which saw the S&P 500 Index (SPX) fall 0.22% and the Dow Jones Industrial Average (DJIA) fall 0.03%. This rise ended a two-day losing streak for the company's stock.
Commission opens antitrust investigation into Align Technology’s conduct regarding Invisalign clear aligners and intra-oral scanners
The European Commission has initiated a formal antitrust investigation into Align Technology, the manufacturer of Invisalign clear aligners and iTero intra-oral scanners. The probe aims to determine if Align Technology has breached EU competition rules by tying its intra-oral scanners to its clear aligners, potentially forcing dental professionals to use iTero scanners to order Invisalign. This investigation, prompted by a competitor's complaint, marks the first formal antitrust inquiry in the medical devices sector and focuses on Align Technology's restrictive interoperability strategy.
Invisalign Maker Align Denies Wrongdoing, Defends Competition Practices As Europe Launches Probe
The European Commission has launched an antitrust investigation into Align Technology Inc., the maker of Invisalign, to determine if the company abused its market position by allegedly requiring dental professionals to use its iTero scanners with Invisalign clear aligners. Align Technology denies any wrongdoing, stating it complies with competition laws and that its market position is driven by product quality and innovation. The company has pledged full cooperation with the investigation and remains confident in its practices.
Is This the Right Time to Hold CRL Stock in Your Portfolio?
Charles River Laboratories International, Inc. (CRL) is positioned for growth due to its Research Models and Services (RMS) business and CRADL adoption, along with strategic deals and a solid financial standing. However, soft biopharma demand and adverse currency fluctuations could impact its results. The company has outperformed its industry and the S&P 500, with a strong earnings yield and consistent earnings surprises.
Align Technology to Announce Second Quarter 2026 Results on July 29, 2026
Align Technology, Inc. (Nasdaq: ALGN) is set to announce its second-quarter 2026 financial results on Wednesday, July 29, 2026, after market close. The company will release results at 4:00 p.m. ET (1:00 p.m. PT) and host a conference call at 4:30 p.m. ET (1:30 p.m. PT) to discuss them. The announcement emphasizes Align Technology's role as a leading global medical device company known for its Invisalign system, iTero scanners, and exocad software.
Align Technology to Announce Second Quarter 2026 Results on July 29, 2026
Align Technology, Inc. (Nasdaq: ALGN) is set to release its second-quarter 2026 financial results on Wednesday, July 29, 2026, after market close. The company will also host a conference call and audio webcast to discuss these results, which will be accessible via their investor relations website. Align Technology is a global medical device company known for its Invisalign System, iTero intraoral scanners, and exocad software.
Align Technology to Announce Second Quarter 2026 Results on July 29, 2026
Align Technology (Nasdaq: ALGN) is scheduled to release its second-quarter 2026 financial results on Wednesday, July 29, 2026, after the market closes. The results will be available on the Investor Relations section of the Align website. Following the release, the company will host a conference call and audio webcast to discuss the financial outcomes.
European Commission opens antitrust investigation of Align Technology clear aligners
The European Commission has launched an antitrust investigation into Align Technology for alleged breaches of EU competition rules. The probe focuses on whether Align has unfairly tied its iTero intra-oral scanners to its Invisalign clear aligners, potentially forcing dental professionals to purchase iTero scanners to order Invisalign products. Align Technology denies wrongdoing, stating its iTero platform supports an open ecosystem and its policies ensure clinical quality, and has committed to cooperating with the investigation.
Align Technology to Announce Second Quarter 2026 Results on July 29, 2026
Align Technology, Inc. (Nasdaq: ALGN) announced that it will report its second quarter 2026 financial results on Wednesday, July 29, 2026, after the close of market. The financial results will be released at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET to discuss the results. The company, known for its Invisalign System and other dental technologies, will make the results and webcast available on its Investor Relations website.
Align Technology to Announce Second Quarter 2026 Results on July 29, 2026
Align Technology (ALGN) will announce its second quarter 2026 financial results on Wednesday, July 29, 2026, after the market closes. The company will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) on the same day to discuss the results, which will be accessible online and via replay.
EU opens antitrust probe into Align Technology over Invisalign, scanner tying
The European Commission has launched an antitrust investigation into U.S.-based Align Technology. The probe will examine whether Align Technology is illegally tying the sale of its iTero intra-oral scanners to its Invisalign clear aligners within the European Economic Area, following a complaint from a competitor. This investigation aims to determine if these practices violate EU competition rules.
Price to book forward of Align Technology, Inc. – NASDAQ:ALGN
This article provides financial information for Align Technology, Inc. (NASDAQ: ALGN), specifically focusing on its "Price to book forward" metric. The content highlights the company's stock information available on TradingView, covering various financial and market data aspects.
Align Technology Statement on European Commission Proceeding
Align Technology (Nasdaq: ALGN) has responded to the European Commission's announcement of an investigation initiated due to a competitor's complaint. The company asserts its commitment to fair competition and compliance with global laws, strongly disputing any claims of unfair practices. Align Technology states its iTero intraoral scanning platform supports an open digital dental ecosystem and that the investigation is purely procedural, not a finding of wrongdoing.
Align Technology Says European Commission Opens Investigation Into Align Technology
Align Technology announced that the European Commission has initiated an investigation into the company. The article from Reuters provides this information concisely, detailing that the news is less than a minute long and copyrighted by Thomson Reuters.
Align Technology Statement on European Commission Proceeding
Align Technology has responded to the European Commission's investigation announcement, which is based on a competitor's complaint. The company asserts its commitment to fair competition and integrity, stating its success derives from product strength and innovation, not unfair practices. Align emphasizes that its iTero intraoral scanning platform supports an open digital dental ecosystem and that the investigation is purely procedural, not a finding of wrongdoing.
Does Dentsply Sirona’s (XRAY) Index Shift Recast Its Role in Dental Innovation Leadership?
Dentsply Sirona (XRAY) has shifted from large- to smaller-cap Russell indexes, including the Russell 2000, and filed a US$161.7 million ESOP shelf registration. This shift, alongside the appointment of a new CFO, could change its institutional ownership and trading patterns, and investors will be looking at how the company confronts persistent top-line weakness and works to stabilize sales and margins. Despite recent revenue softness, the company's digital dentistry push and cost actions are key to its investment narrative, with projections of $3.8 billion revenue by 2029.
Align Technology Statement on European Commission Proceeding
Align Technology (Nasdaq: ALGN) issued a statement in response to the European Commission's announcement of an investigation initiated by a competitor's complaint. The company asserts its commitment to fair competition and disputes claims of unfair practices, emphasizing that its iTero intraoral scanning platform supports an open digital dental ecosystem. Align believes its practices comply with competition laws and will fully cooperate with the Commission's inquiry.
EU Opens In-Depth Antitrust Investigation Into Align Technology’s Invisalign Sales Practices
The European Commission has launched a formal antitrust investigation into Align Technology, the maker of Invisalign, over concerns about its sales practices. Regulators are examining whether the company tied the sales of its orthodontic products with its digital dental scanners, potentially restricting competition and limiting customer choice. This inquiry, initiated after a competitor's complaint, marks the EU's first formal antitrust case in the medical devices sector.
Align Technology Inc. stock outperforms competitors despite losses on the day
Align Technology Inc. (ALGN) shares dropped 2.75% to $168.66, marking its second consecutive day of losses. Despite this, the stock outperformed the broader market, which saw the S&P 500 Index (SPX) rise 0.79% and the Dow Jones Industrial Average (DJIA) increase by 0.26%.
Align Technology (ALGN) Faces Antitrust Scrutiny in Europe
Align Technology (ALGN) is under formal antitrust investigation by the European Commission for allegedly linking its intra-oral scanners to its clear aligners, potentially restricting competition. Despite this, the company, known for Invisalign, maintains a strong GF Score of 89/100 and high profitability. Investors are advised to monitor the investigation's developments due to potential impacts on market position and profitability.
Invisalign Maker Faces EU Antitrust Probe
The European Union's antitrust body has launched an investigation into Align Technology, the maker of Invisalign teeth aligners. The probe will assess whether the company's sales strategy, specifically its potential leveraging of Invisalign's market position to push sales of its iTero intra-oral scanners, violates competition rules. This investigation follows a competitor's complaint and marks the first formal antitrust probe in the medical-devices sector by the European Commission.
US medical device company Align Technology hit with EU probe over possible bundling
Align Technology, a US medical device company, is being investigated by the EU over allegations of abusing its market dominance. The probe focuses on whether the company forces dental professionals to purchase its iTero intra-oral scanners to access its Invisalign clear aligners, marking the first formal antitrust investigation in the medical devices sector.
Align Technology stock falls after EU antitrust probe opens
Align Technology's shares dropped by 2% after the European Commission initiated an antitrust investigation. The probe will examine whether the company is illegally tying the sale of its iTero intra-oral scanners to its Invisalign clear aligners in the European Economic Area, a practice that could violate EU competition laws. This action was triggered by a complaint from a competitor.
EU opens antitrust probe into Align Technology over Invisalign, scanner tying
The European Commission has launched an antitrust investigation into Align Technology, the maker of Invisalign, over concerns that it might be illegally tying its iTero intra-oral scanners to its clear aligners in the European Economic Area. This probe, initiated after a competitor's complaint, will assess whether these practices violate EU competition rules. The investigation reflects the EU's ongoing vigilance against anti-competitive behavior by major tech and healthcare companies.
EU opens antitrust probe into Align Technology over Invisalign, scanner tying
The European Commission has initiated an antitrust investigation into U.S.-based Align Technology. The probe focuses on whether the company is tying its iTero intra-oral scanners to Invisalign clear aligners in the European Economic Area, potentially violating EU competition rules. This investigation was launched following a complaint from a competitor.
US medical device company Align Technology hit with EU probe over possible bundling
The European Union has launched an antitrust probe into US medical device company Align Technology over concerns it may be bundling products. The investigation will examine whether Align Technology is leveraging its market power by requiring dental professionals to purchase its iTero intra-oral scanners if they wish to order the company's Invisalign clear aligners. This marks the first formal antitrust investigation in the medical devices sector by the EU's competition enforcer.
US medical device company Align Technology hit with EU probe over possible bundling
The EU's competition enforcer has launched an antitrust investigation into US medical device company Align Technology. The probe will examine whether the company abused its market dominance by forcing dental professionals to purchase its iTero intra-oral scanners to access its Invisalign clear aligners. This is the first formal antitrust investigation in the medical devices sector by the EU.
Align Technology stock falls after EU antitrust probe opens By Investing.com
Align Technology's stock fell by 2% after the European Commission announced an antitrust investigation into the company. The probe concerns the suspected tying of its iTero intra-oral scanners to Invisalign clear aligners in the European Economic Area, potentially breaching EU competition rules. This investigation was initiated following a complaint from a competitor.
Out of line? EU probes Invisalign dental braces maker for antitrust breach
The European Union has launched an antitrust investigation into Align Technology, the maker of Invisalign clear dental braces, over potential breaches of competition rules. The probe will examine whether the company forces dental professionals to purchase its scanners to order Invisalign products. This marks the EU's first formal antitrust inquiry in the medical devices sector, initiated after a competitor filed a complaint.
Price to earnings forward of Align Technology, Inc. – NASDAQ:ALGN
This article provides financial information for Align Technology, Inc. (NASDAQ: ALGN), specifically focusing on its forward price-to-earnings ratio. It lists the company's stock exchange as Nasdaq and mentions that the market was closed at the time of publication, with no trades.
Price to sales forward of Align Technology, Inc. – NASDAQ:ALGN
This article provides a brief financial overview of Align Technology, Inc. (NASDAQ: ALGN), specifically highlighting its "Price to sales forward" metric. It appears to be an excerpt from a larger financial data platform, likely TradingView, offering quick access to market data and company financials. The content focuses on presenting a single financial indicator for the company.
Align Technology Inc. stock underperforms Monday when compared to competitors
Align Technology Inc. stock (ALGN) fell by 2.80% on Monday to $173.43, contrasting with a positive day for the broader market where the S&P 500 rose by 1.18% and the Dow Jones Industrial Average gained 0.59%. This decline ended the stock's three-day winning streak.
Invisalign Moderate from Align Technology Inc. - tailored for mid-complex cases
Invisalign Moderate, a bestseller from Align Technology, is designed for patients with mid-complex orthodontic needs, offering a defined cap on aligner stages and utilizing a digital workflow with iTero scanners. It bridges the gap between simple cosmetic corrections and comprehensive treatments, providing a clear treatment framework and predictable costs for both clinicians and patients. This product contributes significantly to Align Technology's revenue mix and offers a balanced approach to clear aligner therapy.
3 Reasons to Avoid ALGN and 1 Stock to Buy Instead
This article recommends avoiding Align Technology (ALGN) despite its recent stock performance, citing three main concerns: lackluster revenue growth, shrinking adjusted operating margins, and declining return on invested capital (ROIC). The author suggests that while ALGN's current valuation is fair, the company lacks long-term quality and points readers towards other potential investment opportunities, including Amazon and PayPal of Latin America, and six top stocks identified by an AI system.
European Commission Launches Antitrust Investigation into Align Technology
The European Commission has initiated an antitrust investigation into Align Technology, parent company of Invisalign, over concerns that it has tied its clear aligner products to its iTero intra-oral scanners, potentially harming competition and innovation. The investigation focuses on alleged restrictive interoperability practices and forcing dental professionals to purchase iTero scanners to order Invisalign. Although the company forecasts strong Q2 revenue and reaffirming 2026 growth, this antitrust probe could negatively impact its financial future.
How Align’s Chairman Transition to Kevin Conroy May Reshape Its Governance Story At Align Technology (ALGN)
Align Technology announced that Kevin Conroy will succeed C. Raymond Larkin, Jr. as Chairman, effective July 1, 2026. Conroy brings extensive healthcare and governance experience, having led Exact Sciences to significant revenue and also serving on Abbott Laboratories’ board. This transition is seen as a continuity move rather than a disruption, aiming to bolster Align's investment narrative through operational complements like a new manufacturing facility in Hyderabad, while investors remain mindful of potential margin pressures from price competition.
3 Reasons to Avoid ALGN and 1 Stock to Buy Instead
This article analyzes Align Technology (ALGN), advising investors to avoid it despite recent stock performance. The author highlights three main concerns: lackluster revenue growth, a shrinking adjusted operating margin, and declining return on invested capital (ROIC). Instead, the article suggests looking into other stock opportunities, referencing "the Amazon and PayPal of Latin America" and promoting StockStory's AI-driven stock picks.
Align Technology analyst consensus in focus, shares trade on NASDAQ
Align Technology (US0162551016) starts the new trading week with a clear analyst consensus highlighting cautious expectations for its NASDAQ-listed shares. Analysts project a 12-month price target between $178 and $210, with ratings split between "Buy" and "Hold," reflecting the company's exposure to elective dental spending and macroeconomic conditions. The stock closed at $178.43 on June 26, 2026, with near-term projections suggesting stable trading around $170-$181.
The Invisalign System from Align Technology Inc. - clear aligners with digital planning
The article describes Align Technology Inc.'s Invisalign System, a series of custom clear aligners used for orthodontic treatment. It highlights the digital planning that sets Invisalign apart, reducing chairside adjustments, and details the patient experience and what orthodontists appreciate about the system. The piece also discusses its market role, limitations, and key product facts, positioning Invisalign as a flagship product for Align Technology (NASDAQ: US0162551016).
Align Technology opens the week with a clear earnings calendar, shares trade on Nasdaq
Align Technology's shares are trading on Nasdaq after beating Q1 2026 earnings expectations with a diluted EPS of $2.58. The company's stock price, currently near $178, is above its 50-day and 200-day moving averages, which are identified as support levels. Align Technology generates revenue from its Invisalign system and iTero scanners, and analysts are focused on its upcoming earnings dates and continued growth.
